Ascletis completes US$35 million financing Ascletis announced today the completion of a US$35 million financing. The expenditure was led by C-Bridge Capital, became a member of by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million www.propeciasverige.com . The arises from this funding will be utilized to expand Ascletis' pipeline, strengthen global development capabilities and enhance GMP industrial manufacturing. With the support of the investors, Ascletis is entering an exciting new era now. We're happy that our accomplishments and potential are acknowledged by the traders.
, a leading biotechnology organization in the emerging field of regenerative medicine, today announced today that it offers priced an underwritten public providing of its common stock at a cost of $3.90 per share. Concurrently, the business entered right into a private placement for the sale of common stock at the same cost as the underwritten general public providing. Gross proceeds to the Company from the public offering and the personal placement are anticipated to be approximately $5.5 million in the aggregate. For February 10 Closing of the public offering is scheduled, 2015 at the mercy of customary closing conditions. The Company intends to utilize the net proceeds from the general public offering for continued advancement of product applicants through scientific trials and for working capital and general corporate reasons.